VR23

VR23 is a small molecule that potently inhibits the activities of trypsin-like proteasomes (IC50=1 nM), chymotrypsin-like proteasomes (IC50=50-100 nM), and caspase-like proteasomes (IC50=3 μM) .

Product Specifications

CAS Number

[1624602-30-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Proteasome

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/VR23.html

Purity

99.58

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=S(N1CCN(C2=CC=NC3=CC(Cl)=CC=C23)CC1)(C4=CC=C([N+]([O-])=O)C=C4[N+]([O-])=O)=O

Molecular Formula

C19H16ClN5O6S

Molecular Weight

477.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Pundir S, et al. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res. 2015 Oct 1;75 (19) :4164-4175.|[2]Lee Hoyun, et al. Preparation of quinoline sulfonyl derivatives for the treatment of cancer. From PCT Int. Appl. (2014), WO 2014134705 A1 20140912.